SCHEMBL298844

SCHEMBL298844

O=CN1CCN(c2ccc(F)cc2)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.57
LMNA P02545 4/20 0.57
MAPT P10636 4/20 0.57
MAPK1 P28482 3/20 0.57
HTT P42858 1/20 0.57
GFER P55789 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
POLB P06746 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
AKR1C3 P42330 1/20 0.53
USP2 O75604 1/20 0.53
TP53 P04637 3/20 0.52
KDM4E B2RXH2 2/20 0.52
CA12 O43570 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA9 Q16790 1/20 0.51
GAA P10253 1/20 0.50
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10373626 0.82 MAPT (0.77) ALDH1A1LMNAMAPTMAPK1HTT
SCHEMBL1813762 0.81 MAPK1 (0.42) ALDH1A1LMNAMAPTMAPK1HTT
SCHEMBL4052281 0.81 AKR1C3 (0.52) ALDH1A1LMNAMAPTMAPK1SMN1; SMN2
SCHEMBL10566136 0.80 MAPT (0.52) ALDH1A1LMNAMAPTHTTTDP1
SCHEMBL3917375 0.80 TRIM24 (0.68) ALDH1A1LMNAMAPTMAPK1HTT
SCHEMBL5692418 0.80 TRIM24 (0.68) ALDH1A1SMN1; SMN2KDM4EGAA
SCHEMBL20140813 0.80 TSHR (0.38) ALDH1A1LMNAMAPTMAPK1HTT
SCHEMBL13632364 0.80 AKR1C3 (0.53) ALDH1A1LMNAMAPTMAPK1HTT
SCHEMBL8717879 0.80 AKR1C3 (0.54) ALDH1A1LMNAMAPTHTTSMN1; SMN2
SCHEMBL13632365 0.80 AKR1C3 (0.53) ALDH1A1MAPTSMN1; SMN2AKR1C3USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3564232-B1 BMP-SIGNAL-INHIBITING COMPOUND RIKEN (JP) 2022-01-26 EP claimed
US-10954216-B2 BMP-signal-inhibiting compound RIKEN (JP) 2021-03-23 US claimed
US-20190337926-A1 BMP-SIGNAL-INHIBITING COMPOUND RIKEN (JP) 2019-11-07 US claimed
EP-3564232-A1 BMP-SIGNAL-INHIBITING COMPOUND Riken (JP) 2019-11-06 EP claimed
CN-110337293-A Therapeutic compound 新泽西鲁特格斯州立大学 2019-10-15 CN claimed
CN-103313982-A Phenyl-isoxazole derivatives and process for the preparation thereof IL YANG PHARM CO LTD 2013-09-18 CN claimed
CN-101573344-A Antifungal triazole derivatives, method for the preparation thereof and pharmaceutical composition containing same DAE WOONG PHARMA (KR) 2009-11-04 CN claimed
CN-101255152-A Preparation method and use of piperazine having cytotoxic activity WENZHOU MEDICAL COLLEGE (CN) 2008-09-03 CN claimed
EP-3564232-B1 BMP-SIGNAL-INHIBITING COMPOUND RIKEN (JP) 2022-01-26 EP disclosed
US-10954216-B2 BMP-signal-inhibiting compound RIKEN (JP) 2021-03-23 US disclosed
US-20190337926-A1 BMP-SIGNAL-INHIBITING COMPOUND RIKEN (JP) 2019-11-07 US disclosed
EP-3564232-A1 BMP-SIGNAL-INHIBITING COMPOUND Riken (JP) 2019-11-06 EP disclosed
CN-110337293-A Therapeutic compound 新泽西鲁特格斯州立大学 2019-10-15 CN disclosed
CN-103703002-A Novel compound having parp inhibitory activity SANTEN PHARMACEUTICAL CO LTD 2014-04-02 CN disclosed
WO-2010128163-A2 SMALL MOLECULE INHIBITORS OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION PIKE PHARMA GMBH (CH) 2010-11-11 WO disclosed
US-20090275555-A1 Substituted indole ligands for the ORL-1 receptor BRANE DISCOVERY S.R.L. (IT) 2009-11-05 US disclosed
US-20090275555-A1 Substituted indole ligands for the ORL-1 receptor BRANE DISCOVERY S.R.L. (IT) 2009-11-05 US disclosed
CN-101573344-A Antifungal triazole derivatives, method for the preparation thereof and pharmaceutical composition containing same DAE WOONG PHARMA (KR) 2009-11-04 CN disclosed
CN-101255152-A Preparation method and use of piperazine having cytotoxic activity WENZHOU MEDICAL COLLEGE (CN) 2008-09-03 CN disclosed
CN-1671684-A New benzodioxoles HOFFMANN LA ROCHE (CH) 2005-09-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10954216-B2 BMP-signal-inhibiting compound BMP1, BMP2, BMP4 ALDH1A1 4324/4885LMNA 1065/4885MAPT 4782/4885
US-20090275555-A1 Substituted indole ligands for the ORL-1 receptor OGFRL1, OPRL1, ORMDL3 ALDH1A1 395/4885LMNA 4213/4885MAPT 3308/4885
US-20190337926-A1 BMP-SIGNAL-INHIBITING COMPOUND BMP1, BMP2, BMPR2 ALDH1A1 4102/4885LMNA 567/4885MAPT 4243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.